Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-07-17	$13.94	-1.69%	43,263
26-07-16	$14.18	-1.94%	56,405
26-07-15	$14.46	+0.63%	116,045
26-07-14	$14.37	-2.24%	51,974
26-07-13	$14.70	-1.21%	83,477

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

13.94USD

Average target price

12.00USD

Spread / Average Target

-13.92%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2026-07-17 pm EDT			5-day change	1st Jan Change
13.94 ^USD	-1.69%		-6.32%	-0.11%

Jul. 02	European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading	MT
Jun. 30	Amarin Corporation plc Reaffirms the Proven Guideline-Recommended Role of Vascepa (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape	CI

Market Cap	292M 255M 236M 217M 410M 28.15B 419M 2.82B 1.11B 13.79B 1.1B 1.07B 47.46B	P/E 2026 *	-465x	P/E 2027 *	-697x
Enterprise Value	118M 104M 95.51M 88.04M 166M 11.41B 170M 1.14B 449M 5.59B 445M 435M 19.23B	EV / Sales 2026 *	0.67x	EV / Sales 2027 *	0.66x
Free-Float	89.38%	Yield 2026 *	-	Yield 2027 *	-

Jul. 02	European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading	MT
Jun. 30	Amarin Corporation plc Reaffirms the Proven Guideline-Recommended Role of Vascepa (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape	CI
Jun. 29	European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading	MT
Jun. 23	Top cases on the US Supreme Court's docket	RE
Jun. 22	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
Jun. 18	European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading	MT
Jun. 09	European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading	MT
Jun. 08	European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	MT
Jun. 05	The Jobs Report Just Made the Fed's Life Harder
Jun. 05	To infinity and beyond
Jun. 04	Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case	MT
Jun. 04	Top cases on the US Supreme Court's docket	RE
Jun. 04	Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case	MT

25-10-27	Amarin issues statement supporting FDA's action to revise labeling for fenofibrate drugs reinforcing a lack of cardiovascular benefit	RE
25-06-25	RBC Ups Recordati's Price Target on Cardiovascular Drug European Licensing Deal	MT
23-10-25	Jefferies Downgrades Amarin to Hold From Buy, Cuts Price Target to $1 From $3	MT
23-07-19	Northland Adjusts Price Target on Amarin to $1.25 From $2, Maintains Market Perform Rating	MT
23-01-06	Jefferies Upgrades Amarin to Buy From Hold, Adjusts Price Target to $3 From $1.30	MT

Amarin Corporation plc Stock

Stocks

AMRN

US0231114044

Biotechnology & Medical Research

Valuation: Amarin Corporation plc

Chart: Amarin Corporation plc

Latest news : Amarin Corporation plc

Last Transcript: Amarin Corporation plc

Analysts' recommendations: Amarin Corporation plc

Press Releases: Amarin Corporation plc

News in other languages: Amarin Corporation plc

Quotes and Performance

Course Extremes

Managers and Directors: Amarin Corporation plc

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Jul. 15	Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026	AQ
Jun. 30	Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape	AQ
May. 27	New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia	AQ
Apr. 29	Amarin: Q1 Earnings Snapshot	AQ
Apr. 29	Amarin Reports 2026 First Quarter Financial Results	AQ

Jun. 05	Afternoon Meeting: Los datos de empleo complican la labor de la Fed
Jun. 05	Bourse : Lululemon dévisse, Blackstone se protège, Schneider émet 850 MEUR d'OCEANE
25-07-29	Recordati : firmato contratto di licenza e fornitura con Amarin per 25mln $ (RCO)
25-06-24	Recordati e Amarin commercializzano il farmaco cardiovascolare Vazkepa
22-03-29	Amarin reçoit un remboursement pour VAZKEPA® en Suède

1 day	-1.69%
1 week	-6.32%
Current month	-12.55%
1 month	-13.04%
3 months	-6.94%
6 months	-5.68%
Current year	-0.11%

1 week	13.94	14.97
1 month	13.94	17.25
Current year	12.96	17.31
1 year	12.96	20.9
3 years	7.08	27.4
5 years	7.08	119.4
10 years	7.08	522.4

Manager	Title	Age	Since
Aaron Berg CEO	Chief Executive Officer	63	2024-06-03
Peter Fishman DFI	Director of Finance/CFO	42	2024-10-22
Jonathan Provoost CMP	Compliance Officer	56	2023-11-14

Director	Title	Age	Since
Aaron Berg BRD	Director/Board Member	63	2024-06-03
Louis Sterling BRD	Director/Board Member	47	2023-02-27
Odysseas Kostas CHM	Chairman	51	2023-03-26

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/1/26	Steven Ketchum	Fiscal year	Chief Technology Officer	9,263	0.0022%
7/1/26	David Keenan	Fiscal year	Chief Operating Officer	9,302	0.0022%
7/1/26	Peter Fishman	Fiscal year	Chief Financial Officer	6,100	0.0015%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AMARIN CORPORATION PLC	-1.69%	-6.32%	-11.88%	-51.26%	292M
ARGENX SE	+0.24%	-1.54%	+52.85%	+71.85%	53.83B
WUXI APPTEC CO., LTD.	-7.17%	-4.39%	+42.72%	+73.32%	52.1B
INSMED INCORPORATED	+0.80%	-6.31%	+5.62%	+417.78%	23.48B
BIONTECH SE	-0.09%	-0.01%	-16.85%	-15.41%	23.13B
WUXI BIOLOGICS (CAYMAN) INC.	-5.95%	-2.58%	+29.53%	-9.47%	19.36B
GENMAB A/S	-1.14%	+0.03%	+31.67%	-30.65%	17.56B
PHARMAESSENTIA CORPORATION	-5.16%	-7.00%	+168.44%	+314.96%	15.2B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-6.91%	-5.83%	+25.17%	+644.30%	14.83B
EXELIXIS, INC.	+0.43%	-1.03%	+25.75%	+189.74%	14.06B
Average	-2.66%	-2.99%	+35.30%	+160.52%	23.38B
Weighted average by Cap.	-2.80%	-2.36%	+39.48%	+142.88%

	2026 *	2027 *
Net sales	178M 155M 143M 132M 249M 17.12B 255M 1.71B 674M 8.39B 668M 653M 28.87B	159M 139M 128M 118M 223M 15.3B 227M 1.53B 602M 7.49B 596M 583M 25.79B
Net income	-12.75M -11.14M -10.28M -9.47M -17.86M -1.23B -18.25M -123M -48.32M -601M -47.87M -46.82M -2.07B	-9.04M -7.9M -7.29M -6.72M -12.66M -870M -12.94M -87.11M -34.26M -426M -33.94M -33.2M -1.47B
Net Debt	-174M -152M -140M -129M -244M -16.74B -249M -1.68B -659M -8.2B -653M -639M -28.23B	-187M -164M -151M -139M -263M -18.06B -268M -1.81B -711M -8.84B -704M -689M -30.44B